Shenzhen Hepalink's limited growth potential seems overlooked by investors buying the stock, risking future disappointment when the P/S ratio aligns with growth outlook. Analysts hope for a positive shift in future revenue forecasts to justify current price-to-sales ratio.
海普瑞股票討論區
暫無評論